- Previous Close
0.5850 - Open
0.0510 - Bid 0.0751 x --
- Ask 0.5850 x --
- Day's Range
0.0510 - 0.0510 - 52 Week Range
0.0015 - 3.4200 - Volume
170 - Avg. Volume
724 - Market Cap (intraday)
1.011M - Beta (5Y Monthly) 32.86
- PE Ratio (TTM)
∞ - EPS (TTM)
0.0000 - Earnings Date Jan 14, 2025 - Jan 20, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
StimCell Energetics Inc., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions in the United States. The company develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. It also develops eBalance Home and eBalance Pro System for temporary relief of shoulder, waist, back, neck, arms, and legs. The company was formerly known as Cell MedX Corp. and changed its name to StimCell Energetics Inc. in November 2024. StimCell Energetics Inc. was incorporated in 2010 and is headquartered in Carson City, Nevada.
stimcell.comRecent News: STME
View MorePerformance Overview: STME
Trailing total returns as of 12/12/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STME
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STME
View MoreValuation Measures
Market Cap
1.01M
Enterprise Value
1.31M
Trailing P/E
30.12
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
34.55k
Price/Book (mrq)
--
Enterprise Value/Revenue
103.69k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-421.58%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-132.45k
Diluted EPS (ttm)
0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
20.55k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.11M